Literature DB >> 14610128

[Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype.

T van Veen1, L van Winsen, J B A Crusius, N F Kalkers, F Barkhof, A S Peña, C H Polman, B M J Uitdehaag.   

Abstract

BACKGROUND: Both multiple sclerosis (MS) susceptibility and MS clinical phenotype are in part genetically determined. [Alpha]B-crystallin is a candidate autoantigen in MS, and there are three polymorphisms in the promoter region of the encoding gene (CRYAB): at positions -C249G, -C650G, and -A652G.
METHODS: These polymorphisms were studied in sporadic cases of MS, assessing disease susceptibility, clinical phenotype, and MRI appearance.
RESULTS: The CRYAB polymorphisms influenced susceptibility as well as disease expression in MS.
CONCLUSION: Carriers of the rare allele CRYAB-650*C had an increased likelihood of a noninflammatory, neurodegenerative phenotype characterized by a relatively rapid, primary progressive clinical disease course.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610128     DOI: 10.1212/01.wnl.0000091861.27246.9e

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Analysing the effect of candidate genes on complex traits: an application in multiple sclerosis.

Authors:  Tineke Hooper-van Veen; Johannes Berkhof; Chris H Polman; Bernard M J Uitdehaag
Journal:  Immunogenetics       Date:  2006-04-13       Impact factor: 2.846

Review 2.  A molecular trio in relapse and remission in multiple sclerosis.

Authors:  Lawrence Steinman
Journal:  Nat Rev Immunol       Date:  2009-06       Impact factor: 53.106

3.  Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study.

Authors:  M H Sombekke; M M Vellinga; B M J Uitdehaag; F Barkhof; C H Polman; D Arteta; D Tejedor; A Martinez; J B A Crusius; A S Peña; J J G Geurts; H Vrenken
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

Review 4.  Cat-Map: putting cataract on the map.

Authors:  Alan Shiels; Thomas M Bennett; J Fielding Hejtmancik
Journal:  Mol Vis       Date:  2010-10-08       Impact factor: 2.367

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.